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ABSTRACT
Objective Kawasaki disease (KD) is an acute vasculitis
that causes coronary artery aneurysms (CAA) in young
children. Previous studies have emphasised poor long-term
outcomes for those with severe CAA. Little is known about
the fate of those without CAA or patients with regressed
CAA. We aimed to study long-term cardiovascular status
after KD by examining the relationship between coronary
artery (CA) status, endothelial injury, systemic inﬂammatory
markers, cardiovascular risk factors (CRF), pulse-wave
velocity (PWV) and carotid intima media thickness (cIMT)
after KD.
Methods Circulating endothelial cells (CECs), endothelial
microparticles (EMPs), soluble cell-adhesion molecules
cytokines, CRF, PWV and cIMT were compared between
patients with KD and healthy controls (HC). CA status of
the patients with KD was classiﬁed as CAA present (CAA+)
or absent (CAA−) according to their worst-ever CA status.
Data are median (range).
Results Ninety-two KD subjects were studied, aged
11.9 years (4.3–32.2), 8.3 years (1.0–30.7) from KD
diagnosis. 54 (59%) were CAA−, and 38 (41%) were CAA
+. There were 51 demographically similar HC. Patients with
KD had higher CECs than HC (p=0.00003), most evident
in the CAA+ group (p=0.00009), but also higher in the
CAA− group than HC (p=0.0010). Patients with persistent
CAA had the highest CECs, but even those with regressed
CAA had higher CECs than HC (p=0.011). CD105 EMPs
were also higher in the KD group versus HC (p=0.04),
particularly in the CAA+ group (p=0.02), with similar
ﬁndings for soluble vascular cell adhesion molecule 1 and
soluble intercellular adhesion molecule 1. There was no
difference in PWV, cIMT, CRF or in markers of systemic
inﬂammation in the patients with KD (CAA+ or CAA−)
compared with HC.
Conclusions Markers of endothelial injury persist
for years after KD, including in a subset of patients
without CAA.
INTRODUCTION
Kawasaki disease (KD) is a self-limiting medium
vessel vasculitis of unknown aetiology affecting
8.39/100 000 children under the age of ﬁve per
year in the UK;1 22.5/100 000 in white
Californians, with higher incidence in Asian/Paciﬁc
Islanders (50.4/100 000) and 29.8/100 000 in the
black population.2 The highest incidence is in
Japanese: 243.1/100 000 aged 0–4 years in 2011
and 264.8 in 2012.3 Coronary artery aneurysms
(CAA) occur in 15%–25% of untreated patients;
2%–3% of untreated cases die as a result of coron-
ary vasculitis.4 Despite the effectiveness of
intravenous immunoglobulin (IVIG),4 20% of cases
are IVIG resistant, and are at even higher risk of
coronary complications. As more children with KD
are advancing into adulthood, further studies are
needed to improve our understanding of long-term
cardiovascular sequelae.4–7 KD vasculopathy differs
from atherosclerosis in several key characteristics.8
Histologically, the vasculopathy of KD is charac-
terised by an acute, predominantly neutrophilic
necrotising vasculitis targeting the luminal coronary
endothelium. Subsequently, a later subacute/chronic
vasculitis ensues, targeting the adventitia, with
myoﬁbroblastic proliferation causing progressive
arterial stenoses over many years. Importantly,
histological features of true atherosclerosis such as
lipid-laden macrophages are usually absent.8
The prognosis for patients with giant (≥8 mm)
CAA is extremely worrying, with 88% 30-year sur-
vival, 16% myocardial infarction rate and 59%
requiring revascularisation within a 25-year
follow-up.9 Common sense dictates that patients
with persistent CAA require lifelong follow-up. It
remains unclear, however, what long-term manage-
ment is required for patients who never had CAA
or in whom CAA have regressed. Although many
patients with CAA undergo regression of aneurys-
mal dilatation, the coronaries remain abnormally
thickened, and vessel-wall calciﬁcation is often
detected.6 The long-term consequences of these
changes remain largely unknown. The American
Heart Association (AHA) have issued clinical guide-
lines for the long-term follow-up and management
of patients with KD,10 recently adopted in the
UK.4 These recommendations are not based on
robust scientiﬁc data. To date, there has only been a
single small study of late KD vascular outcome in
the UK.11 Long-term studies to inform follow-up
strategies for patients with KD in the UK are, there-
fore, required. We conducted the current study to
address this unmet clinical need.
We hypothesised that chronic vasculitis persists
years after the acute KD presentation, and is detect-
able using novel biomarkers of endothelial injury.
We conducted a study to examine the relationship
between coronary artery (CA) status, endothelial
injury, systemic inﬂammatory markers, cardiovascu-
lar risk, pulse-wave velocity (PWV) and carotid
intima media thickness (cIMT) years after KD.
METHODS
This was an observational comparative study, with
ethical approval (08/H0713/80). All participants
provided fully informed written consent; assent,
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where appropriate, was also obtained from children under the
age of 16 years. After an overnight fast, subjects attended the
Somers Clinical Research Facility at Great Ormond St Hospital
NHS Foundation Trust (GOSH) between January 2009 and May
2013 for a single research assessment. Deidentiﬁed clinical data
collated included age, sex, ethnicity, age at KD diagnosis, features
of KD at presentation, treatments past and present, CA status,
body mass index, blood pressure and smoking status.
Patients with KD
Inclusion criteria were complete KD (≥12 months previously) as
deﬁned by AHA criteria, fever lasting at least 5 days plus four of
ﬁve principal clinical criteria: (1) rash, (2) bilateral conjunctivitis
without exudate, (3) inﬂammation of oral mucosa, (4) cervical
lymphadenopathy and (5) extremity changes.10 Patients with
atypical KD with fewer than four of the clinical features, but in
the presence of CAA, were also eligible for inclusion.4 Exclusions
were presence of any signiﬁcant acute or chronic comorbidity,
including intercurrent infection. Patients with KD were recruited
from two main sources: (1) GOSH and (2) via advertisement by
the Kawasaki Syndrome Support Group (http://www.kssg.org.
uk). CA status from the original clinical presentation for each
patient was ascertained from independent direct scrutiny of
patients’ medical records by a senior vasculitis expert (PAB) and a
senior paediatric cardiologist (GC); any discrepant cases were
discussed to achieve consensus. All clinical and scientiﬁc studies
were performed blind to the subject status, however.
Deﬁnition of CA status and IVIG resistance
The primary data analysis was performed according to the
worst-ever CAA status of the patients with KD, deﬁned at any
stage over the disease course using recommended AHA cri-
teria.10 Thus, CAA+ patients were those where any of the fol-
lowing three conditions were met: (1) z score of left anterior
descending (LAD) or right CA (RCA) ≥2.5, (2) abnormal CAs
as per Japanese Ministry of Health criteria (internal diameter
>3 mm in children under the age of 5 years, >4 mm for chil-
dren 5 years and above, internal diameter greater than 1.5 times
the size of an adjacent segment or obvious irregularity of the
CA lumen) or (3) z score for LAD or RCA 2–2.5 in the presence
of at least two other suggestive features (perivascular brightness,
lack of arterial tapering, decreased LV function, mitral regurgita-
tion or pericardial effusion). CAA− patients did not have any of
the above features at any stage of their disease.
CAA on the day of study were deﬁned as CA internal diam-
eter ≥2 SD above the mean for age-adjusted body surface area,
calculated using the web tool http://:www.paramaterz.com,12
and included those with true CAA (internal diameter Z score
>3, giant aneurysms as internal diameter >8 mm) and those
with CA ectasia (internal vessel diameter Z score ≥2, but <3),10
or other obvious signiﬁcant luminal abnormality.
For the purposes of a subgroup analysis of the CAA+ patients,
subjects who still had echocardiographic evidence of CAA on the
day of study were deﬁned as persistent CAA; CAA+ patients
who no longer had evidence of CAA were deﬁned as regressed
CAA.
IVIG resistance was deﬁned as those who received more than
one dose of IVIG or one dose of IVIG plus second-line or third-
line treatment (other than aspirin or other non-steroidal anti-
inﬂammatory drugs).4
Controls
Age-similar (at least within 2 years) and sex-matched controls
were recruited from healthy unaffected siblings of patients with
KD. A pilot study comparing the preliminary data obtained
from the ﬁrst 19 such controls found no difference in any bio-
marker compared with other matched paediatric controls from
previous studies from our group.
Conventional cardiovascular risk factor assessments
Echocardiography was performed and interpreted in all subjects
by trained senior paediatric cardiologists (GC, TM and JM) who
were blinded to the subject’s status using a predeﬁned protocol
that assessed CA and ventricular dimensions, conventional para-
meters of systolic and diastolic function (fractional shortening,
EF, mitral inﬂow, pulsed wave tissue Doppler imaging annular
velocities) and ventricular myocardial deformation using speckle-
tracking imaging13; 12-lead resting ECG and fasting lipids (total
cholesterol, low-density lipoprotein (LDL), high-density lipopro-
tein (HDL), very low-density lipoprotein (VLDL) and triglycer-
ides (TG)) were also assessed using routine methodologies (see
online supplementary methods). Resting (minimum of 15 min)
blood pressure was measured using an oscillometric manual
sphygmomanometer (Greenlight 300; ACCOSON, Essex, UK).
Assessment of inﬂammatory indices
High-sensitivity C reactive protein (hs-CRP), serum amyloid A
(SAA), tumour necrosis factor α, interleukin-1β, 6, 8 and 10,
monocyte chemoattractant protein-1, vascular endothelial
growth factor (VEGF), angiopoietin 1 and 2, soluble E-selectin,
soluble intercellular adhesion molecule 1 (sICAM-1), soluble vas-
cular cell adhesion molecule 1 (sVCAM-1), soluble P-selectin and
thrombomodulin were assessed using a validated commercial
multiarray detection system based on electrochemiluminescence
technology (SECTOR Imager 2400; MesoScale Discovery) (see
online supplementary methods).
Assessment of endothelial injury
Circulating endothelial cells
Circulating endothelial cells (CECs) were identiﬁed with
CD146-immunomagnetic bead extraction based on an inter-
national consensus standardised protocol,14 15 as described in
the online supplementary methods.
Endothelial microparticles
Annexin V-positive endothelial microparticles (EMPs) expres-
sing CD105, E-selectin, ICAM-1, VCAM-1, CD144, CD31, but
negative for the platelet marker CD42a, were quantiﬁed from
platelet poor plasma using a BD FACSArray ﬂow cytometer as
previously described by our group,16 17 (see online supplemen-
tary methods).
Vascular stiffness and cIMT
Carotid-femoral and carotid-radial PWVs were assessed by a
trained investigator (VS) using the Vicorder device (Skidmore
Medical) as per manufacturer’s instructions, and in accordance
with AHA recommendations18 (see online supplementary
methods). Measurement of cIMT was assessed by experienced
vascular technicians using a standardised imaging protocol (see
online supplementary methods).
Statistical analysis
Sample size calculations were based on CECs (the primary
outcome measure). Pilot data from the ﬁrst 30 patients with KD
suggested that CECs were not normally distributed. Natural
logarithmic transformation to normality provided an SD of 0.9
for the healthy controls (n=19) and 1.2 for patients with KD,
and suggested that 40 subjects in each group were required to
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detect a doubling of average CECs in each KD subgroup versus
controls with 90% power, signiﬁcance 0.05. Making adjustment
for non-normality and the need to either use non-parametric
tests or to transform prior to analysis, this number increased to
47 per group.19 Thus, we aimed to recruit 80–100 KD subjects
and 50 healthy controls. Numeric data were expressed as
median and range, and were compared between groups using
the Kruskal–Wallis and Mann–Whitney tests. Fisher’s exact test
was used to compare categorical variables. All differences,
including 95% CIs, were calculated. Spearman correlation coef-
ﬁcient was used to explore the relationship between parameters.
p Values of <0.05 were considered signiﬁcant for CECs; ana-
lysis of all the other indices was considered exploratory, and
therefore, p values were not adjusted for multiple comparisons.
Analysis of covariance was used to compare the slope of PWV
versus age between the groups using linear regression.
Multivariable linear regression was used to assess the relation-
ship between CECs (dependent variable) and predictor vari-
ables: healthy control or KD, presence of CAA, male sex, age at
diagnosis and at study assessment, IVIG resistance, length of
follow-up from KD diagnosis and inﬂammatory status (hs-CRP
or SAA). CECs were log-transformed, and hence, model coefﬁ-
cients were exponentiated to represent fold-increase in median
CEC between groups. Statistical analyses were performed using
GraphPad Prism V.4.0, SPSS V.22 and R V.3.1.2.
RESULTS
Demographics
Of 150 invites sent out, 92 positive responses and agreement to
participate in the study were returned, yielding 92 patients with
KD: 54 CAA− and 38 CAA+, and 51 healthy controls. The
reason why some patients did not respond to the study invite
was not formally ascertained; however, there was no obvious
bias in CAA status in those who failed to respond. There was no
difference in any demographic parameter, body mass index,
blood pressure or smoking status between the KD group and
controls (table 1). While the CAA+ group was slightly younger,
this did not reach statistical signiﬁcance. The CAA+ group was
also younger at KD onset than the CAA− group. There were no
other signiﬁcant demographic differences between the controls
and the KD subgroups. Subjects in both groups were predomin-
antly Caucasian. Sixteen per cent in the control group were
non-Caucasian; their ethnicities were Asian (n=4) or Afro–
Caribbean (n=3); and 17% of the KD group were
non-Caucasian; their ethnicities were Asian (n=8), Afro–
Caribbean (n=6) and Brazilian (n=1).
KD clinical features
Eighty-three out of 92 (90%) had complete KD; the remaining
nine cases (10%) had atypical KD. Seventy-ﬁve received IVIG
(82%); eight (9%) did not receive IVIG; in seven cases, the KD
treatment status was unknown. Forty-eight cases (64%) were
IVIG resistant; 63% of the IVIG-resistant group developed CAA,
and 15% of the non-IVIG-resistant group developed CAA (differ-
ence 48%, 95% CI 25% to 63%, p<0.0001). Table 2 summarises
the CA status of the 92 patients with KD. Twenty-two of the KD
group were currently receiving medication. For the CAA+
group, 12 were on low-dose aspirin alone; three on aspirin and
warfarin; one on aspirin and clopidogrel; one on aspirin, carvedi-
lol and lisinopril and two on clopidogrel alone. For the CAA−
group, one patient was on warfarin (for deep vein thrombosis
(DVT) that complicated the initial KD episode), and one was
treated with verapamil (for Wolff–Parkinson–White syndrome).
None of the healthy controls were receiving medication.
Routine laboratory indices
Table 3 summarises the routine laboratory indices between the
KD and control groups. There was no signiﬁcant difference in
hs-CRP, SAA, fasting total cholesterol, LDL cholesterol, HDL
cholesterol or TG between healthy controls and patients with
KD, with or without CAA.
Circulating inﬂammatory indices
The results are summarised in table 4. VEGF was higher in the
CAA+ group than controls. There was no signiﬁcant difference
between healthy controls and patients with KD, with or without
CAA, in any other inﬂammatory parameter studied.
Assessment of endothelial injury
Circulating endothelial cells
Patients with KD had higher CECs than the healthy controls
(table 5 and ﬁgure 1A). While the CAA+ group had the highest
CECs, CAA− patients also had higher CECs compared with the
controls. Subgroup analysis of the CAA+ group revealed
patients with persistent CAA had the highest CECs, but those
with regressed CAA also had signiﬁcantly higher CECs than
healthy controls (ﬁgure 1B). There was no signiﬁcant correlation
between CECs and time from the acute KD episode (ﬁgure 1C).
Table 1 Demographics of patients with KD and healthy controls
Healthy controls
N=51
KD
N=92
KD vs controls
p Value
CAA−
N=54
CAA− vs controls
p Value
CAA+
N=38
CAA+ vs controls
p Value
Age at study (years, range) 13.5 (4.9, 30.3) 11.9 (4.3, 32.2) 0.51 13.4 (5.3, 32.2) 0.61 10.4 (4.3, 24.4) 0.051
Males (%) 53% 51% 0.86 25/54 46% 0.56 22/38 58% 0.67
Body mass index, kg/m2 20.2 (13.5, 35.5) 19.2 (11.2, 33.6) 0.97 21.1 (14.0, 33.6) 0.21 17.3 (11.2, 29.7) 0.13
Systolic BP 110 (90, 133) 110 (78, 140) 0.72 110 (81, 137) 0.50 100 (78, 140) 0.12
Diastolic BP 60 (47, 80) 60 (40, 95) 0.99 60 (43, 95) 0.90 60 (40, 80) 1.0
Caucasian 82% 79% 0.82 87% 0.78 71% 0.46
Non-Caucasian 16% 17% 11% 24%
Ethnicity unknown 2% 5% 2% 5%
Smoker (%) 0% 3% 0.55 4% 0.50 3% 0.43
Age at KD diagnosis (years) – 4.9 (0.18, 11.3) – 3.0 (0.3, 11.3) – 0.9 (0.2, 8.8) –
Time of study (years) after KD – 8.3 (1.0, 30.7) – 8.5 (2.0, 30.7) – 7.8 (1.0, 23.5) –
All data are median (range), unless otherwise specified.
BP, blood pressure; CAA, coronary artery aneurysms; KD, Kawasaki disease.
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EMPs and soluble adhesion molecules
CD105 EMPs were higher in the KD group versus controls (table
5), particularly in the CAA+ group (ﬁgure 2A). Patients with per-
sistent CAA had the highest CD105 EMPs, although patients
with regressed CAA also had higher CD105 EMP than controls
(ﬁgure 2B). sVCAM-1 was higher in the KD group versus con-
trols (table 5), and even higher in the CAA+ group (table 5 and
ﬁgure 2C). Patients with regressed CAA had the highest
sVCAM-1 (ﬁgure 2D). sICAM-1 was higher in the CAA+ group
versus the controls and the CAA− group (table 5 and ﬁgure 2E);
patients with KD with persistent CAA had the highest sICAM-1
(ﬁgure 2F).
Predictors of CEC counts
There was no signiﬁcant association between CEC and current
age, male sex, age at diagnosis, IVIG resistance, length of
follow-up from KD episode, hs-CRP or SAA in univariable
models (see online supplementary table S1). Both subject status
(KD or healthy control) and presence of CAA were univariably
signiﬁcantly associated with CEC count. In the multivariable
model, KD was associated with a 64% increase on average in
CEC count (95% CI 12% to 140%, p=0.0001), and presence
of CAA remained independently associated with a further 59%
increase (95% CI 6% to 140%, p=0.026). After accounting for
these two variables, none of the other factors were independ-
ently predictive of CEC count.
Structural peripheral arterial parameters
There was a strong positive association between age and carotid-
femoral PWV for all subject groups: r2=0.65 for controls,
r2=0.62 for CAA− and r2=0.73 for CAA+; p<0.0001 for all
(ﬁgure 3). There was, however, no difference in the PWV (table
5 and ﬁgure 3) or cIMT (table 5) between the controls and the
patients with KD, with or without CAA.
DISCUSSION
The long-term cardiovascular outcome for paediatric survivors
of KD is an important concern. It is known that the prognosis
for patients with persistent CAA remains guarded, particularly
for those with giant CAA since myocardial infarction occurs in
16%–31%.9 20 Much less is known about the fate of those with
regressed CAA or those who never developed CAA. We con-
ducted a long-term follow-up study of KD in a UK-based
Table 2 Coronary artery status of the KD group (n=92)
CAA status of the KD group (n=92) n (% of all KD patients)
CAA+ 38 (41)
CAA >8 mm 7 (8)
Persistent CAA 7 (8)
Regressed CAA 0 (0)
CAA <8 mm 31 (34)
Persistent CAA 10 (11)
Regressed CAA 21 (23)
CAA− 54 (59)
CAA+: CAA defined at any stage after the initial KD episode (see Methods). CAA−:
no evidence of coronary aneurysm at any stage. Persistent CAA (n=17, 19%): any
CAA+ subject who still had echocardiographic evidence of CAA on the day of study
(see Methods). Regressed CAA (n=21, 23%): CAA+ subjects whose aneurysms had
regressed on echocardiography on the day of study. 6/38 of the CAA+ patients
developed coronary stenosis; these included 4/7 of the patients with giant (>8 mm)
CAA, three of whom required a revascularisation procedure.
CAA, coronary artery aneurysm; KD, Kawasaki disease.
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population. Using a multimodal approach to the assessment of
cardiovascular health, we observed elevation of markers of
endothelial injury, a median of 8.3 (1.0–30.7) years after KD.
CECs were signiﬁcantly higher in KD than controls, and were
highest in the CAA+ group, but also elevated in patients with
regressed CAA and in the CAA− group (ﬁgure 1A, B). This
observation was corroborated by further evidence of persistent
markers of endothelial injury in KD versus controls from three
other circulating indices: CD105 EMP, sVCAM-1 and sICAM-1,
particularly in the CAA+ group (ﬁgure 2) and by the observa-
tion that VEGF was higher in the CAA+ group than controls.
Patients with regressed CAA also had signiﬁcantly higher circu-
lating CD105 EMPs and sVCAM-1 (ﬁgures 2B, D). Despite
this, we did not detect any evidence of altered peripheral arter-
ial health (PWV and cIMT) in the patients with KD or any per-
turbation in conventional cardiovascular risk factors. These
novel observations could have implications for long-term moni-
toring, follow-up and secondary prevention of cardiovascular
events in survivors of KD.
CECs are mature cells that have become detached from the
vessel wall, and are associated with vascular injury, particularly
in diseases where endothelial injury is central to the pathogen-
esis, such as the systemic vasculitides.16 21 Nakatani et al22
demonstrated high CECs in acute KD complicated by CAA, but
also in patients without CAA. Yu et al23 demonstrated that these
CECs expressed higher levels of inducible-nitric oxide synthase,
mirroring ﬁndings in lesional coronary vasculitis observed at
postmortem. These CECs carry surface-bound S100 and related
proteins, including MRP-8/MRP-14,24 S100A12 25 and its
receptor, RAGE (receptor for advanced glycation endpro-
ducts),25 26 and their levels correlate with the severity of coron-
ary vasculitis. These studies suggest that CECs detach from
medium-sized arteries as a result of neutrophil-endothelial inter-
actions mediated by S100 proteins. CECs appear highest in
those with CAA, but are also elevated in patients with acute KD
without CAA,22 and are higher in those with IVIG resistance.26
CECs may, therefore, be a good biomarker of acute coronary
vasculitis.
Our study now suggests that CECs remain elevated for years
after KD, including in some patients who never had any evi-
dence of CAA. This ﬁnding aligns well with the observation that
coronary endothelial dysfunction assessed using paradoxical
vasoconstriction response to intracoronary acetylcholine chal-
lenge is known to persist for many years in patients with KD
with aneurysms.27 28 It is still unclear, however, how CECs
relate to earlier studies that used ﬂow-mediated dilatation
(FMD) in the brachial artery. Dhillon et al11 observed that FMD
of the brachial artery was markedly reduced in patients with KD
compared with control subjects many years after the illness,
even in patients without detectable early CA involvement. In
contrast, McCrindle et al29 did not demonstrate any differences
in brachial artery reactivity following KD. Brachial artery FMD,
cIMT and PWV are unlikely to be reliable surrogates for asses-
sing coronary vascular health after KD since these techniques
were developed for the assessment of vascular health in athero-
sclerosis. The peripheral arteries are not typically affected in
KD, and hence, these indices are not good surrogates for the
study of late-KD coronary vasculopathy.
We did not demonstrate any evidence of systemic inﬂamma-
tion (table 4) or cardiovascular risk factors to account for the
elevated CECs we observed. We suggest that our observations
are consistent with an ongoing active subclinical vasculitis
because there was no signiﬁcant correlation between CECs and
time from acute KD diagnosis (ﬁgure 1C), and we also
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Table 5 Endothelial injury markers, platelet microparticles, arterial stiffness and carotid IMT in the KD group and controls
Healthy controls
Median (range)
All patients with KD
Median (range)
KD vs controls
p Value (95% CI of diff)
KD CAA−
Median (range)
CAA− vs controls
p Value (95% CI of diff)
KD CAA+
Median (range)
CAA+ vs controls p Value
(95% CI of diff)
p Value
Kruskal–Wallis*
CECs (cells/mL) 12 (0, 32)
(n=49)
24 (0, 224)
(n=89)
p=0.00003 (4 to 16) 20 (4, 128)
(n=53)
p=0.0010 (4 to 12) 30 (0, 224)
(n=36)
p=0.00009 (8 to 44) p<0.0001
Microparticles (×103/mL) plasma
Total annexin V 990 (160, 6160) 970 (1190, 5410) p=0.83 (−250 to 220) 850 (190, 5410) p=0.42 (−360 to 160) 990 (230, 4360) p=0.54 (−200 to 400) 0.37
CD54 (ICAM-1) 0.97 (0, 27.00) 0.87 (0, 18.00) p=0.82 (−0.40 to 0.34) 0.85 (0, 18.00) p=0.86 (−0.50 to 0.43) 1.10 (0, 9.11) p=0.83 (−0.62 to 0.46) 0.97
CD62E (E-sel) 3.92 (0, 49.34) 2.87 (0, 22.37) p=0.40 (−1.89 to 0.53) 3.13 (0, 22.37) p=0.84 (1.75 to 0.96) 1.87 (0, 16.98) p=0.16 (−2.97 to 0.19) 0.30
CD105 0 (0, 206.50) 1.60 (0, 186.80) p=0.04 (0.03 to 1.95) 1.50 (0, 94.64) p=0.14 (−0.02 to 1.67) 2.97 (0, 186.80) p=0.02 (0.01 to 6.00) 0.07
CD62P (P-sel) 0 (0, 12.90) 0 (0, 15.17) p=0.59 (−0.01 to 0.01) 0 (0, 15.17) p=0.94 (−0.03 to 0.08) 0 (0, 8.62) p=0.24 (−0.03 to 0.24) 0.41
CD144 0.20 (0, 12.36) 0.32 (0, 155.20) p=0.42 (−0.02 to 0.29) 0.90 (0, 21.74) p=0.24 (−0.004 to 0.71) 0 (0, 155.20) p=1.0 (−0.02 to 0.02) 0.43
CD31 20.59 (0, 556.50) 14.18 (0, 981.00) p=0.98 (−8.37 to 6.74) 13.62 (0, 981.00) p=0.89 (−8.57 to 9.13) 17.63 (0, 258.30) p=0.83 (−13.7 to 6.48) 0.93
VCAM-1 (CD106) 0 (0, 56.06) 0 (0, 110.50) p=0.70 (−0.03 to 0.003) 0 (0, 5.76) p=0.93 (−0.04 to 0.02) 0 (0, 110.50) p=0.54 (−0.01 to 0.04) 0.79
CD42a (platelet MP) 24.93 (0, 930.70)
(n=47)
14.04 (0, 586.50)
(n=87)
p=0.26 (−15.88 to 2.02) 13.50 (0, 586.50)
(n=52)
p=0.16 (−20.10 to 1.04) 13.61 (0, 509.90)
(n=35)
p=0.66 (−16.25 to 6.74) 0.36
Soluble adhesion molecules (ng/mL)
sICAM-1 251 (186, 504) 260 (131, 452) p=0.58 (−16 to 30) 250 (153, 416) p=0.46 (−31 to 16) 300 (131, 452) p=0.04 (1 to 59) 0.03
sVCAM-1 408 (261, 1066) 465 (253, 880) p=0.007 (15 to 79) 454 (253, 714) p=0.08 (−4 to 66) 484 (274, 880) p=0.0022 (30 to 113) 0.006
sE-Sel 13 (5, 62) 16 (5, 59) p=0.31 (−1 to 4) 15 (5, 59) p=0.49 (−2 to 4) 17 (5, 42) p=0.27 (−2 to 5) 0.52
sP-Sel 70 (19, 262)
(n=48)
82 (22, 204)
(n=89)
p=0.10 (−2 to 23) 86 (23, 204)
(n=53)
p=0.09 (−2 to 28) 77 (22, 139)
(n=37)
p=0.28 (−7 to 22) 0.19
Carotid-radial PWV (m/s) 7.30 (4.70, 9.60)
(n=51)
7.40 (4.60, 11.20)
(n=91)
p=0.40 (−0.30 to 0.50) 7.50 (4.60, 11.20)
(n=53)
p=0.25 (−0.20 to 0.70) 7.40 (4.90, 11.20)
(n=38)
p=0.86 (−0.50 to 0.50) 0.46
Carotid-femoral PWV (m/s) 5.40 (4.00, 8.40)
(n=51)
5.40 (3.80, 9.00)
(n=91)
p=0.69 (−0.40 to 0.30) 5.70 (3.90, 9.00)
(n=53)
p=0.58 (−0.30 to 0.60) 5.10 (3.80, 7.00)
(n=38)
p=0.13 (−0.80 to 0.10) 0.15
Right CCA IMT (mm) 0.47 (0.40, 0.60)
(n=42)
0.47 (0.39, 0.58)
(n=78)
p=0.77 (−0.02 to 0.01) 0.47 (0.39, 0.58)
(n=45)
p=0.59 (−0.02 to 0.01) 0.47 (0.39, 0.57)
(n=33)
p=0.92 (−0.2 to 0.2) 0.75
Left CCA IMT (mm) 0.46 (0.41, 0.60)
(n=40)
0.46 (0.37, 0.58)
(n=76)
p=0.97 (−0.01 to 0.01) 0.47 (0.37, 0.53)
(n=44)
p=0.99 (−0.02 to 0.02) 0.46 (0.39, 0.58)
(n=32)
p=0.95 (−0.02 to 0.02) 1.00
All values are median (range) unless otherwise specified. Number (n) of subjects in each group as specified per test.
*p Values from Kruskal–Wallis test comparing three groups: controls, CAA− and CAA+ (CA status at initial disease presentation). 95% CI of diff: 95% CI of the difference of median. Statistically significant results are in bold.
CAA, coronary artery aneurysms; CCA, common carotid artery; CECs, circulating endothelial cells; E-Sel, E-selectin; ICAM, intercellular adhesion molecule; IMT, intima media thickness; KD, Kawasaki disease; P-Sel, P-selectin; PWV, pulse-wave velocity;
s, soluble; VCAM, vascular cell adhesion molecule.
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consistently observed elevated soluble adhesion molecules
(sVCAM-1 and sICAM-1) and CD105 EMP in the KD CAA+
group. We also observed signiﬁcantly higher levels of VEGF in
the CAA+ group. This latter observation could be explained by
an attempt at ongoing endothelial repair/remodelling in patients
with active subclinical vasculitis, as suggested by our previous
studies of systemic vasculitis in children.16 It could also indicate
an ongoing, and possibly permanent, disturbance in endothelial
cell homoeostasis. Future studies examining the mechanisms
driving this chronic endothelial injury and the prognostic rele-
vance of this ﬁnding are now required. While we did not
measure circulating S100 proteins or their expression on CECs,
it is possible that this mechanism could account for the persist-
ently high CEC levels.
Although we did (as expected) observe a strong positive rela-
tionship between PWV and age, there was no difference in
patients with KD (with or without CAA) and healthy controls
(ﬁgure 3). Similarly, we did not detect any difference in cIMT.
These ﬁndings are in agreement with a recently published large
study of cardiovascular health in 203 predominantly Caucasian
North American patients with KD, a median of 11.6 years (1.2–
26 years) after acute KD;30 the authors concluded that patients
with KD without CAA or with CA ectasia could be reassured,
and may not need specialised surveillance. Moreover, we did
not observe any difference in lipid proﬁle between patients with
KD and controls again, in agreement with the study conducted
by Selamet Tierney et al.30 While we cannot yet conclude that
patients with high CECs after KD are at higher risk of cardio-
vascular events, our study now provides a scientiﬁc rationale for
the AHA recommendation for follow-up even for those without
CAA,10 since persistence of subclinical vasculitis in an important
subset of patients is likely to act in concert with traditional car-
diovascular risk factors to adversely inﬂuence long-term coron-
ary prognosis. Since it is currently not possible to clinically
distinguish those with elevated CECs from patients with KD as
a whole, we suggest that all patients with KD (irrespective of
Figure 1 Circulating endothelial cells. (A) CECs were highest in the KD CAA+ group (CAA+ vs HC, 95% CI of difference in medians 8 to 44), but
were not signiﬁcantly higher than the CAA− group; CECs were also higher in the CAA− group versus HC (95% CI of difference in medians 4 to 12).
(B) Patients with persistent CAA had even higher levels of CECs (persistent CAA vs HC, 95% CI of difference in medians 16 to 60) and higher versus
CAA−. Those with regressed CAA also had high CECs (regressed CAA vs HC, 95% CI of difference in medians 0.000032 to 24) that were not
signiﬁcantly different from those with persistent CAA (95% CI of difference in medians −4 to 48) or the CAA− subjects. (C) There was no signiﬁcant
correlation between CECs and time from the acute KD episode to study: r=−0.13, 95% CI −0.23 to 0.44, p=0.36 for the CEC– group; r=0.12, 95%
CI −0.40 to 0.44, p=0.50 for the CEC+ group. Horizontal lines represent median and IQR. CAA, coronary artery aneurysms; CECs, circulating
endothelial cells; HC, healthy control; KD, Kawasaki disease.
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Figure 2 EMP and soluble adhesion molecules. (A) KD CAA+ patients had higher CD105 EMP than HC (95% CI of difference 0.01 to 6.00×103/
mL), but there was no signiﬁcant difference when the CAA+ group was compared with CAA− patients. CAA− patients did not signiﬁcantly differ
from HC. (B) Patients with KD with persistent CAA had the highest CD105 EMP, although this did not reach statistical signiﬁcance compared with
controls (95% CI of difference in median −0.00005 to 6.04×103/mL). Patients with KD with regressed CAA had signiﬁcantly higher CD105 EMP
(median 2.59×103/mL) than HC (0.00×103/mL) (95% CI of difference in median −0.00006 to 10.49), but not compared with the persistent CAA
group (95% CI of difference in median −5.68 to 10.40) or the CAA− group. (C) sVCAM-1 was signiﬁcantly higher in the CAA+ group versus HC,
but this was not signiﬁcantly higher when compared with the CAA− group.(D) sVCAM-1 was particularly high in those with regressed CAA (Regr
CAA: vs HC (95% CI of difference in median 32.3 to 144.6 ng/mL) and vs CAA−), but was not different from those with persistent CAA (95% CI of
difference in median −44.4 to 111.1 ng/mL). (E) sICAM-1 was higher in the KD CAA+ group (vs HC (95% CI of difference in median 1 to 59 ng/mL)
and vs CAA−). (F) sICAM-1 was highest in those with persistent CAA (Pers CAA: vs HC (95% CI of difference in median 2 to 86 ng/mL) and higher
than the CAA− group). There was no difference in sICAM-1 levels between the persistent and regressed CAA groups (95% CI of difference in
median −76 to 31 ng/mL), and no signiﬁcant difference between Regr CAA and controls (95% CI of difference in median −11 to 52 ng/mL).
Horizontal lines represent median and IQR. CAA, coronary artery aneurysms; EMP, endothelial microparticles; HC, healthy control; KD, Kawasaki
disease; Pers, persistent; Regr, regressed; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule.
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CAA status) require long-term monitoring. In particular, the
current practice of discharging those with ‘resolved’ aneurysms
from care no longer seems prudent. Long-term surveillance and
registries to follow these patients into adulthood to monitor
outcomes are required.
Limitations
Since our study assessed medical records from multiple centres
going back over 30 years, it is possible that some patients with
minor degrees of coronary vasculitis could have been misclassi-
ﬁed, although medical records were assessed independently by
two experienced clinicians, thus limiting any potential bias.
Second, since our study was not a single-centre study, sequential
detailed echocardiographic data were not available to us to
study CAA regression rates and the potential inﬂuence of that
on CEC counts, an area worthy of a further prospective study.
Third, for practical reasons, we used healthy siblings of index
KD cases as controls. As yet undeﬁned genetic factors could,
therefore, have inﬂuenced the cardiovascular status of these
healthy sibling controls. We consider this to be unlikely,
however, even more so because there was no signal of this in a
pilot study comparing these controls with other healthy young
controls from separate studies. Lastly, regarding peripheral
arterial health, the median time after KD was relatively
short, although there was no signal whatsoever that PWV
(ﬁgure 3) or cIMT (table 5) deviated from controls even 20–
30 years after KD.
CONCLUSIONS
In conclusion, we have conducted a follow-up study of KD and
found: (1) evidence of persistent endothelial injury years after
KD in a subset of patients both with and without CAA and (2)
no evidence of structural peripheral arterial disease. Future
studies now need to validate the relevance of CECs as a poten-
tially important prognostic biomarker of late-KD vasculopathy.
Key messages
What is already known on this subject?
Kawasaki disease (KD) is a self-limiting medium vessel vasculitis
of unknown aetiology, affecting predominantly children under
the age of 5 years, resulting in coronary artery aneurysms (CAA)
in approximately 25% of untreated patients. There is a need to
identify patients at risk of late KD vasculopathy to inform
clinical strategies for surveillance and prevention of late
cardiovascular events.
What might this study add?
This study examined circulating endothelial cells (CECs) years
after KD. CECs were increased in patients with KD, were highest
in those with CAA, but were also elevated in some patients
without CAA, compatible with a state of persistent subclinical
vasculitis years after the acute disease. In contrast, arterial
stiffness, carotid intima media thickness and conventional
cardiovascular risk factors were no different from controls.
How might this impact on clinical practice?
The signiﬁcance of patients having high CECs is unknown. Our
study does, however, provide a scientiﬁc rationale for
recommending lifelong follow-up of all patients with KD.
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